As the pipeline for biologic drugs continues to flow, employers are looking to biosimilars for help in controlling the ever-increasing financial burden on employee benefits. Biosimilars are considered “highly similar” to FDA-approved biologic originator drugs, with no clinically meaningful differences in terms of safety, purity and potency. Currently, over 80% of biosimilars run through the medical claims side. Employers need to require that clinical protocols are clearly defined in carrier contracts and mandate the appropriate use of biosimilars for patient efficacy and cost effective outcomes. Biosimilars can reduce pharmacy benefit costs significantly, just as generic drugs have done.

View Agenda